WTO Exemptions To Give Leg-Up To Bangladeshi, Indian Firms?
This article was originally published in PharmAsia News
The WTO Council's recent decision to grant least-developed country members an exemption from implementing intellectual property provisions, such as patents, on medicines is expected to give Bangladesh's up-and-coming pharma industry valuable buffer time to catch up with and possibly take on rivals in the region.
You may also be interested in...
Bangladesh's HCV market report card currently reads along these lines: generic versions of Sovaldi and Daklinza have made significant gains leaving interferon by the wayside, while generic Harvoni has had a quiet run. But, the arrival of cut-price Epclusa generics could bring change, besides putting the spotlight on the growing prowess of the South Asian nation's pharmaceutical industry.
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
The head of global vaccine and plasma segments, bioprocessing, at German multinational Merck discusses key aspects around evolving vaccine manufacturing to improve the efficiency and speed of response during a pandemic. Pre-existing manufacturing platforms, the executive says, could compress process development work and fast-track scale-up.